ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.56 HKD | +3.33% |
|
+0.76% | -15.11% |
| Mar. 22 | Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 | MT |
| Mar. 21 | Zylox-Tonbridge Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- With an enterprise value anticipated at 4.78 times the sales for the current fiscal year, the company turns out to be overvalued.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.11% | 428M | - | ||
| +10.49% | 125B | A- | ||
| -7.14% | 10.97B | A- | ||
| +4.05% | 8.99B | C | ||
| +35.39% | 5.38B | B+ | ||
| -14.29% | 4.86B | C | ||
| +8.31% | 3.43B | C- | ||
| -8.87% | 2.78B | B- | ||
| -4.33% | 2.22B | - | - | |
| -0.90% | 2.21B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2190 Stock
- Ratings Zylox-Tonbridge Medical Technology Co., Ltd.